Antholeth Leckie
Acute Care · Orlando, FLNPI 1073222873
Payments from drug & device makers
Across 165 payments — averaging $25.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$921
- GSK$566
- Harmony Biosciences LLC$454
- Regeneron Healthcare Solutions, Inc.$334
- Electromed, Inc.$301
- Takeda Pharmaceuticals U.S.A., Inc.$297
- plus $1K from 25 others
What the payments were for
- Food & beverage$4,267100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 9 | $921 |
| GSK | 24 | $566 |
| Harmony Biosciences LLC | 22 | $454 |
| Regeneron Healthcare Solutions, Inc. | 16 | $334 |
| Electromed, Inc. | 21 | $301 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $297 |
| Pulmonx Corporation | 9 | $215 |
| Boehringer Ingelheim | 9 | $200 |
| Grifols USA, LLC | 6 | $144 |
| Baxter Healthcare | 4 | $97 |
| Jazz Pharmaceuticals Inc. | 3 | $82 |
| Insmed, Inc. | 3 | $67 |
| Merck | 2 | $64 |
| Novartis | 3 | $60 |
| Mallinckrodt Hospital Products Inc. | 2 | $54 |
| United Therapeutics Corporation | 2 | $45 |
| Philips North America LLC | 2 | $39 |
| Mylan Specialty L.p. | 2 | $37 |
| Gilead | 2 | $35 |
| Tactile Systems Technology Inc | 2 | $32 |
| Sanofi | 1 | $28 |
| Actelion Pharmaceuticals US, Inc. | 1 | $28 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $24 |
| Chiesi USA, Inc. | 1 | $23 |
| Vivus LLC | 1 | $22 |
| Phadia US Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $18 |
| Verona Pharma, Inc. | 1 | $17 |
| UCB, Inc. | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Inogen, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,267 in reported general payments places this provider in the 90th percentile of 1,150 acute care providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 220 | $202,664 |
| Breo ElliptaFluticasone/Vilanterol | 100 | $63,405 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 73 | $52,054 |
| Spiriva RespimatTiotropium Bromide | 39 | $32,612 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 34 | $29,240 |
| SymbicortBudesonide/Formoterol Fumarate | 69 | $24,060 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 39 | $19,073 |
| Advair HfaFluticasone Propion/Salmeterol | 34 | $14,774 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 393 | $9,243 |
| Wixela InhubFluticasone Propion/Salmeterol | 54 | $7,696 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 41 | $6,215 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 18 | $2,877 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 40 | $2,443 |
| Roflumilast | 16 | $1,644 |
| Fluticasone Propionate | 119 | $1,624 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $566 | $285,142359 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $921 | $76,114142 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $200 | $61,85273 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,150 acute care providers in Florida.
Other acute care in Orlando
- Melisa WilsonOrlando$3.6M
- Ali SobhOrlando$15K
- Lamisa RaysideOrlando$7K
- Amanda PeacockJacksonville$81K
- Katrina RileyTampa$66K
- Diane GrayLake Mary$49K
- Heather RamousSafety Harbor$38K
- Melanie WeresJacksonville$37K
- Jayne JaramilloJacksonville$27K
- Melissa HamiltonTampa$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.